News

Medtronic has a historically high 3% yield and is just two years away from becoming a Dividend King.

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $350.16, moving 4.51% from the previous trading session.

BOTZ offers diversified exposure to a robotics boom fueled by AI, humanoid robots and industrial automation, as the sector rapidly evolves.

Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.

Sands Capital, an investment management company, released its second-quarter 2026 investor letter for “Sands Capital Global Growth Fund”. The letter can be downloaded here. Global Growth seeks the best growth businesses worldwide, leveraging a research team that explores both developed and emerging markets for sustainable competitive advantages. In the quarter, global equities rebounded strongly, driven […]

Intuitive Surgical's flywheel isn't selling new surgical robots, its selling parts and services to support the ones it has already sold.

You might regret ignoring these companies at current levels.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

The stock has dropped more than 30% this year.

Intuitive Surgical has notably underperformed the Health Care Equipment industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.

Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $372.6, indicating a +1.51% shift from the previous trading day.

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.

Intuitive Surgical (ISRG) has been back in focus after reporting another quarter of double digit revenue and procedure growth, supported by adoption of its da Vinci 5, single port system and Ion lung biopsy platform. Despite the strong quarterly update, Intuitive Surgical’s share price has been under pressure, with the stock down 34.09% on a year to date share price return and down 21.38% on a 1-year total shareholder return. This contrasts with its 16.27% total shareholder return over three...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.

ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.

Intuitive Surgical leads surgical robotics with faster procedure growth and recurring revenue, while Medtronic offers a cheaper, diversified growth profile.

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Its growth profile stands well above major sector peers.

While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.

Insider disposals, bearish options positioning, and fading retail sentiment are flashing caution on NVIDIA even as the fundamentals keep accelerating. Here is why our model reads that tension as an opportunity rather than a warning.

According to the average brokerage recommendation (ABR), one should invest in Intuitive Surgical (ISRG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

MedTech investors are facing an increasingly difficult choice. On one side is Abbott Laboratories (NYSE:ABT), a diversified healthcare company steadily expanding across diagnostics, medical devices, and nutrition. On the other hand is Intuitive Surgical (NASDAQ:ISRG), the undisputed leader in robotic surgery, whose premium valuation reflects expectations for years of continued growth. Both companies delivered strong […]

Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth. Some businesses are emerging from temporary industry slowdowns, while others continue compounding through durable competitive advantages. Danaher Corporation (NYSE:DHR) and Intuitive Surgical (NASDAQ:ISRG) illustrate that contrast perfectly. Danaher (NYSE:DHR) is beginning to benefit from improving life sciences spending […]

Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher’s (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) continues to hold a dominant position in robotic surgery through factors such as its highly recurring revenue model. Both companies […]

In the past year, Intuitive Surgical has seen procedure growth in the US slow, particularly in bariatric surgeries influenced by rising GLP-1 use, even as its operating margin widened for three consecutive years and management raised its 2026 non-GAAP gross margin forecast while continuing to fund R&D. An interesting tension is emerging as hospital capital budget constraints and shifting procedure mix weigh on growth expectations, even while analysts remain optimistic and management...